Figure 1.

Effect of Blinatumomab and Inotuzumab ozogamicin (InO) on a cancer cell and the mechanism of tumor cell escape. (a) Blinatumomab in therapeutic context. Blinatumomab is a mediator between CD19 antigen on T lymphocytes and CD19 antigen localized on cancer cells. Effect of connection is cancer cell death, caused by cytotoxic activity of T lymphocyte; (b) Resistance to Blinatumomab. No CD19 antigen on cancer cells leads to no connection between T lymphocyte and cancer cell, where there is no cell death; (c) Inotuzumab ozogamicin (InO) in therapeutic context. When CD22 antigens are found on cancer cells, InO binds, and it causes the production of intracellularly unconjugated calicheamicin, which causes blast cell death. (d) Resistance to InO. InO has no effect when CD22 antigens are not present on cancer cells. Image created with BioRender.com, accessed on 29 January 2022.